Abstract: The present invention relates to compounds of Formula (I): where R1, R2, X, s, and p are as defined herein. The present invention also relates to compounds of Formula (II), Formula (III), and: where R1a, R1b, R1d, R2a, R2b, R3b, X, Z, Z1, Z2, s, and p are as defined herein. Methods of using these compounds to regulate Cav2.2.target double-stranded RNA and to treat diseases and disorders, e.g., chronic pain, are also disclosed.

Abstract: Systems and methods are provided for determining whether to extend a recording of a media asset based on analyzing user data. A media guidance application may determine that a media asset is recording during a scheduled time slot that has a start time and an end time. The media guidance application may determine that the media asset will be transmitted outside of the scheduled time slot based on inputs from a plurality of users. In response to determining that the media asset will be transmitted outside of the scheduled time, the media guidance application may extend the recording of the media asset beyond the scheduled time slot by a predetermined amount of time.

Abstract: Systems and methods are provided for determining whether to extend a recording of a media asset based on analyzing user data. A media guidance application may determine that a media asset is recording during a scheduled time slot that has a start time and an end time. The media guidance application may determine that the media asset will be transmitted outside of the scheduled time slot based on inputs from a plurality of users. In response to determining that the media asset will be transmitted outside of the scheduled time, the media guidance application may extend the recording of the media asset beyond the scheduled time slot by a predetermined amount of time.

Abstract: The present invention relates to a tablet comprising Afatinib or a pharmaceutically acceptable salt thereof, wherein the tablet is obtained by direct compression. The present invention further relates to a process for manufacturing a tablet of the invention as well as the use of the tablet of the invention.

Abstract: Systems, methods and computer software are disclosed for providing a bubble network are described. In one embodiment, a method is disclosed including providing an isolated base station having a coverage area, providing a local HetNet Gateway (HNG) disposed within the coverage area and in communication with the isolated base station, providing a local Evolved Packet Core (EPC) in communication with the local HNG and disposed within the coverage area, and wherein the bubble network is disconnected from a mobile operator core network.

Abstract: Disclosed are compositions and methods for treating, preventing, or reducing neuropathic pain or severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in a patient. The compositions contain, or the methods involve, compounds that inhibit neuropilin receptor 1 signaling. The compounds are present in amounts effective to treat, prevent, or reduce one or more symptoms associated with neuropathic pain or SARS-CoV-2 in a patient.

Abstract: This invention is in the field of medicinal chemistry. In particular, the invention relates to a new class of small-molecules having a piperazine or piperidine structure which function as either inhibitors of pan-T-type calcium channel activity (e.g., CaV3.1 voltage gated calcium channel activity) (e.g., CaV3.2 voltage gated calcium channel activity) (e.g., CaV3.3 voltage gated calcium channel activity) (e.g., depolarization-induced calcium influx) or specific inhibitors of CaV3.2 voltage gated calcium channel activity, and their use as therapeutics for the treatment and/or prevention of pan-T-type calcium channel related pain (e.g., CaV3.1 related pain) (e.g., CaV3.2 related pain) (e.g., CaV3.3 related pain) (e.g., HIV-associated peripheral sensory neuropathy, chemotherapy-induced peripheral neuropathy (CIPN), spinal nerve ligation (SNL) induced neuropathy) (e.g., tonic, neuropathic, and/or inflammatory pain) and related conditions.

Abstract: Dysregulation of TAF1 function by various mechanisms can lead to disease in the central nervous system, such as the TAF1 Intellectual Disability (ID) Syndrome which currently has no therapeutic treatments. The present invention indicates that a novel T-type calcium channel enhancer, such as SAK3, has disease-modifying effects in animal models of TAF1 editing. In addition, the present invention provides insights into the molecular mechanism by which SAK3 exerts in pharmacologic effects. Moreover, the present findings imply that the T-Type voltage-gated calcium channels are novel molecular targets to develop therapeutics to treat TAF1 ID syndrome and that SAK3 is an attractive drug candidate to treat TAF1 associated neurologic disorders.

Abstract: This invention is in the field of medicinal chemistry. In particular, the invention relates to a new class of small-molecules having a piperazine or piperidine structure which function as inhibitors of the CaV3.2 voltage gated calcium channel activity (e.g., depolarization-induced calcium influx), and their use as therapeutics for the treatment and/or prevention of CaV3.2 related pain e g., HIV-associated peripheral sensory neuropathy, chemotherapy-induced peripheral neuropathy (CIPN), spinal nerve ligation (SNL) induced neuropathy) and related conditions.

Abstract: Devices and systems for treating based on light therapy are disclosed. One example device includes an eyewear configured for placement in front of an eye to allow light to reach the eye, and one or more filters having transmission spectra within a range that approximately spans 450 to 570 nm associated with blue or green light. The one or more filters is configured to block light spectra outside of said range and to allow the blue or green light to reach the eye for administering light therapy to a subject exhibiting pain.

Abstract: A communications backpack is disclosed. In one embodiment, the communications backpack includes a backpack; a Radio Area Network (RAN) device in mechanical communication with the backpack; a mini-server in mechanical communication with the backpack and in electrical communication with the RAN device; at least one hot swappable battery in mechanical communication with the backpack and in electrical communication with the RAN device and the mini-server; at least two antennas, wherein the two antennas are stored in a first position alongside the backpack and are movable to a second position where the two antennas are coupled to the backpack and in electrical communication with the RAN device; and wherein the communications backpack provides a coverage area of up to 3 kilometers (km).

Abstract: Systems, methods and computer software are disclosed for providing a bubble network are described. In one embodiment, a method is disclosed including providing an isolated base station having a coverage area, providing a local HetNet Gateway (HNG) disposed within the coverage area and in communication with the isolated base station, providing a local Evolved Packet Core (EPC) in communication with the local HNG and disposed within the coverage area, and wherein the bubble network is disconnected from a mobile operator core network.

Abstract: Systems, methods and computer software are disclosed for providing a bubble network are described. In one embodiment, a method is disclosed including providing an isolated base station having a coverage area, providing a local HetNet Gateway (HNG) disposed within the coverage area and in communication with the isolated base station, providing a local Evolved Packet Core (EPC) in communication with the local HNG and disposed within the coverage area, and wherein the bubble network is disconnected from a mobile operator core network.

Abstract: The present invention relates to a tablet comprising Afatinib or a pharmaceutically acceptable salt thereof, wherein the tablet is obtained by direct compression. The present invention further relates to a process for manufacturing a tablet of the invention as well as the use of the tablet of the invention.

Abstract: The present invention relates to a stable liquid pharmaceutical composition of pemetrexed for parenteral administration. The invention provides composition comprising pemetrexed diacid, an organic amine and cyclodextrin. The composition may further comprise an inert gas. The composition can be ready to use infusion solution of pemetrexed diacid or liquid concentrate formulation to be diluted before administration to the patient. The present invention further relates to a process for manufacturing the compositions as well as use of the compositions of the invention for the treatment of malignant pleural mesothelioma and non-small cell lung cancer.

Abstract: Systems and methods are provided for determining whether to extend a recording of a media asset based on analyzing user data. A media guidance application may determine that a media asset is recording during a scheduled time slot that has a start time and an end time. The media guidance application may determine that the media asset will be transmitted outside of the scheduled time slot based on inputs from a plurality of users. In response to determining that the media asset will be transmitted outside of the scheduled time, the media guidance application may extend the recording of the media asset beyond the scheduled time slot by a predetermined amount of time.

Abstract: Systems and methods are provided for determining whether to extend a recording of a media asset based on analyzing user data. A media guidance application may determine that a media asset is recording during a scheduled time slot that has a start time and an end time. The media guidance application may determine that the media asset will be transmitted outside of the scheduled time slot based on inputs from a plurality of users. In response to determining that the media asset will be transmitted outside of the scheduled time, the media guidance application may extend the recording of the media asset beyond the scheduled time slot by a predetermined amount of time.

Abstract: This invention is in the field of medicinal chemistry. In particular, the invention relates to a new class of small-molecules having a piperidinyl-benzoimidazole structure which function as antagonists of small ubiquitin like modifier (SUMO) related modification (SUMOylation) of collapsin response mediator protein 2 (CRMP2), and their use as therapeutics for the treatment of voltage gated sodium channel 1.7 (Nav1.7) related itch, anosmia, migraine event, and/or pain (e.g., neuropathic pain).

Abstract: The present invention provides compounds that can modulate the amount of Nav1.7 protein, a key protein in pain signaling, that is present in the cellular surface and methods for using such compounds. In particular, compounds of the invention modulate the amount of Nav1.7 protein on the cellular surface by modulating SUMOylation of CRMP2. Thus, compounds of the invention can be used to treat various clinical conditions associated with the presence and/or activation of Nav1.7 protein on the cellular surface and/or SUMOylation of CRMP2.

Abstract: Devices and systems for treating based on light therapy are disclosed. One example device includes an eyewear configured for placement in front of an eye to allow light to reach the eye, and one or more filters having transmission spectra within a range that approximately spans 450 to 570 nm associated with blue or green light. The one or more filters is configured to block light spectra outside of said range and to allow the blue or green light to reach the eye for administering light therapy to a subject exhibiting pain.